Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

RxPros vs Vita Bella

RxPros
Graded #128

Higher grade

vs+4.3999999999999915
Vita Bella
Graded #233

Lower grade

The verdict

RxPros takes it — 69.3/100 to 64.9/100.

RxPros grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RxPros (rxpros.com) is a Wyoming-incorporated compounded GLP-1 telehealth platform (RxPros LLC, 1309 Coffeen Ave Ste 15880, Sheridan, WY 82801).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueRxPros +27
71
44
Dose & formulationRxPros +12
64
52
Clinical oversightEven
91
91
Labs & monitoringVita Bella +24
53
77
FulfillmentVita Bella +9
74
83
Contract termsEven
47
47
RxPros · left barVita Bella · right bar

The numbers

MetricRxProsVita Bella
WeighScore69.3/10064.9/100
GradeCC
Scorecard rank#128#233
Semaglutide$100/mo (annual plan, compounded)Not disclosed
Tirzepatide$145/mo (annual plan, compounded)$159/mo (2.5 mg dose, plus a separate fee, compounded)
CoverageCoverage not published46 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
RxPros

Graded #128 · C

Strengths

  • $99.99/month compounded semaglutide — among the cheapest in the US compounded telehealth market
  • $144.97/month compounded tirzepatide — at the lower end of the compounded tirzepatide range
  • LegitScript Certified
  • Named legal entity (RxPros LLC) with a physical Wyoming address
  • Overnight cold-packed shipping disclosed — important for GLP-1 cold-chain integrity

Where it loses points

  • Per-state availability not listed — verify your state ships before committing
  • Specific 503A pharmacy partners not named
  • Lab work not included as standard
  • LegitScript certification number not displayed (seal only)
  • Lowest headline prices ($99.99 sema / $144.97 tirz) require annual prepay; intro-first-month/quarterly tier is $134.99 sema / $224.99 tirz
Vita Bella

Graded #233 · C

Strengths

  • Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
  • Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
  • Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
  • Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
  • Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge

Where it loses points

  • Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
  • Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
  • Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard